Low‐dose empagliflozin as adjunct‐to‐insulin therapy in type 1 diabetes: A valid modelling and simulation analysis to confirm efficacy

AIM: To confirm the observed reduction in HbA1c for the 2.5 mg dose in EASE‐3 by modelling and simulation analyses. MATERIALS AND METHODS: Independent of data from EASE‐3 that tested 2.5 mg, we simulated the effect of a 2.5 mg dose through patient‐level, exposure‐response modelling in the EASE‐2 cli...

Descripción completa

Detalles Bibliográficos
Autores principales: Perkins, Bruce A., Soleymanlou, Nima, Rosenstock, Julio, Skyler, Jay S., Laffel, Lori M., Liesenfeld, Karl‐Heinz, Neubacher, Dietmar, Riggs, Matthew M., Johnston, Curtis K., Eudy‐Byrne, Rena J., Elmokadem, Ahmed, George, Jyothis T., Marquard, Jan, Nock, Valerie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7064984/
https://www.ncbi.nlm.nih.gov/pubmed/31858718
http://dx.doi.org/10.1111/dom.13945

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7064984/
https://www.ncbi.nlm.nih.gov/pubmed/31858718
http://dx.doi.org/10.1111/dom.13945

Ejemplares similares